News
PDMR dealings
New York/London, 25 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 24 June 2019, Panetta...
Newly Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana’s Oral Monoclonal Antibody Platform
Third party research conducted by leading U.S. institutions to be published in a peer reviewed journal Crohn’s & Colitis 360 shows orally administered anti-CD3 resulted in anti-inflammatory gene expression with no serious treatment related adverse events up to a...
PDMR Dealings
New York/London, 11 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 10 June 2019, Panetta...
PDMR Dealings
New York/London, 7 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 5 June 2019, Panetta Partners...
PDMR dealings
New York/London, 3 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 31 May 2019, Panetta Partners...
Results of Annual General Meeting
Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology and immunology, today announces that at the Annual General Meeting of the...
Tiziana Life Sciences to Present at the 9th Annual LD Micro Invitational
New York / London May 28, 2018 Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced that it will be presenting at...
Notice of Annual General Meeting
Tiziana Life Sciences plc (the "Company") Notice of Annual General Meeting Tiziana Life Sciences plc announces that its Annual General Meeting will be held at 10:00 a.m. on Friday 31 May 2019 at the offices of Cooley (UK) LLP, Dashwood, 69 Old Broad Street, London...
PDMR dealings
Tiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) PDMR dealings New York/London, 1 May 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative...
Update on IND Application for Oral Formulation of Foralumab for Treatment of NASH
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS...
PDMR dealings
Tiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) New York/London, 25 April 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative...
Tiziana Reports Encouraging Interim Clinical Data from an Ongoing Phase 2a Trial with milciclib in Advanced Liver Cancer Patients
Tiziana Reports encouraging interim clinical data from an ongoing Phase 2a Clinical Trial with Milciclib in Patients with advanced liver cancer 80% of patients who completed treatment within the trial’s timeframe requested to continue treatment on compassionate use...
TR-1 – Notification of Major Holdings
TR-1 – Notification of Major Holdings New York/London, 15 April 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today...
Tiziana announces financial results for year ending 31 December 2018
Tiziana Life Sciences PLC ("Tiziana" or the "Company") Financial Results for the Year Ended 31 December 2018 London, 4 April 2019 – Tiziana Life Sciences plc (AIM: TILS), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology...
Tiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS...
Directorate Change
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Directorate Change New York/London, 7 February 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM:...
Exercise of Warrants & Issue of Equity
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc ("Tiziana" or the "Company") Exercise of Warrants & Issue of Equity New York/London, 11 December 2018 - Tiziana Life Sciences plc...
Tiziana Completes Patient Enrollment in a Phase 2a Trial to Evaluate Tolerability and Anti-Tumor Activity of Milciclib in Hepatocellular Carcinoma (HCC)
New York/London, 3 December 2018 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that patient enrollment in the...
Tiziana Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human Anti-Cluster Definition 3 Monoclonal Antibody (anti-CD3 mAb), in Healthy Volunteers
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc(“Tiziana” or the “Company”) Tiziana Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human...
Tiziana Life Sciences plc Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq listed ADSs
London, 26 November 2018 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company”), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that in...
Tiziana Announces Closing of Offering and Resulting Total Voting Rights
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT...
Tiziana Announces temporary reduction to exercise prices of outstanding warrants
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT...
Tiziana Announces Pricing of Offering and Warrant Conversion Raising in Aggregate £4.51 million of New Equity Capital, Approval to List on the Nasdaq Global Market and Loan Conversion Extinguishing £1.39 million of Debt
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT...
Equity Placing to raise US$1,500,000
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc ("Tiziana" or the "Company") London, October 26, 2018 - Tiziana Life Sciences plc (AIM: TILS), a UK biotechnology company that focuses...